New hope for relapsed leukemia: experimental drug AZD4512 enters human trials
NCT ID NCT07109219
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 25 times
Summary
This study tests a new drug called AZD4512 in people with a hard-to-treat blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to other treatments. The goal is to see if the drug is safe and how well it works, either alone or with other cancer medicines. About 83 participants aged 12 and older will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGDuarte, California, 91010, United States
-
Research Site
WITHDRAWNJacksonville, Florida, 32224, United States
-
Research Site
RECRUITINGChicago, Illinois, 60611, United States
-
Research Site
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site
RECRUITINGFranklin, Tennessee, 37067, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
NOT_YET_RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
-
Research Site
RECRUITINGToronto, Ontario, M5G 1X6, Canada
-
Research Site
NOT_YET_RECRUITINGGuangzhou, 510515, China
-
Research Site
NOT_YET_RECRUITINGTianjin, 301600, China
-
Research Site
RECRUITINGBunkyō City, 113-8677, Japan
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 06591, South Korea
-
Research Site
RECRUITINGSeoul, 3722, South Korea
-
Research Site
NOT_YET_RECRUITINGBadalona(Barcelona), 08916, Spain
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGSalamanca, 37007, Spain
-
Research Site
RECRUITINGSantander, 39008, Spain
-
Research Site
WITHDRAWNValencia, 46026, Spain
-
Research Site
RECRUITINGTaichung, 40705, Taiwan
-
Research Site
RECRUITINGTaipei, 106, Taiwan
-
Research Site
RECRUITINGBloomsbury, W1T 7HA, United Kingdom
-
Research Site
RECRUITINGManchester, M20 4BX, United Kingdom
Conditions
Explore the condition pages connected to this study.